🇺🇸 FDA
Patent

US 11332721

Recombinant respiratory syncytial virus strains with mutations in the M2-2 ORF providing a range of attenuation phenotypes

granted A61KA61K2039/522A61K2039/5254

Quick answer

US patent 11332721 (Recombinant respiratory syncytial virus strains with mutations in the M2-2 ORF providing a range of attenuation phenotypes) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue May 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K2039/522, A61K2039/5254, A61K2039/543, A61K39/12